Ventricular fibrillation and catecholamine responses during profound hypothermia in dogs.
D000433:1-Propanol / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001784:Blood Gas Analysis; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000378:metabolism*; D002496:Central Venous Pressure / Q000187:drug effects; D004285:Dogs; D005019:Ethyl Ethers; D005021:Ethylamines / Q000627:therapeutic use; D006221:Halothane; D006339:Heart Rate / Q000187:drug effects; D007036:Hypothermia, Induced / Q000009:adverse effects*; D008680:Metaraminol / Q000494:pharmacology / Q000627:therapeutic use*; D008781:Methyltyrosines / Q000494:pharmacology / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D014508:Urea / Q000627:therapeutic use*; D014693:Ventricular Fibrillation / Q000517:prevention & control*
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D005019:Ethyl Ethers; D005021:Ethylamines; D008781:Methyltyrosines; D013449:Sulfonamides; D008680:Metaraminol; D014508:Urea; D000433:1-Propanol; D011433:Propranolol; D006221:Halothane